Ocugen Doses First Patient in Trial of Potential Eye Disease Drug

MT newswire2026/09/01 11:35

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

07:35 AM EDT, 09/01/2026 (MT Newswires) -- Ocugen Inc (OCGN) has dosed its first patient in a phase 3 trial of its OCU410 modifier gene therapy as a potential treatment for geographic atrophy secondary to dry age-related macular degeneration, the company said Tuesday. The drug is designed as a one-time subretinal gene therapy, the company said. The placebo-controlled study has enrolled 237 patients, the company said. The company plans to file a biologics license application for the therapy in 2028, it said.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

The U.S. Energy Information Administration (EIA) has raised its forecast for average Brent crude oil prices in 2026 and 2027 to $97 and $86, respectively, reflecting pressures from global inventory declines, Middle East supply disruptions, and rising transportation costs. As oil production in the Middle East gradually recovers and global inventories rebound from low levels, the EIA expects the average spot price of Brent crude to fall to $87 per barrel in the second quarter of 2027, and further decline to $77 per barrel by the fourth quarter.

华尔街见闻•2026/11/10 18:41